Global pharma corporation Moderna is progressing its combined Covid-19 and influenza vaccine, known as the Superjab, to late-stage trials – and there is an opportunity for Australia to play a key role in its production.
Seasonal burden eased
This development could be a significant stride towards alleviating the seasonal burden on healthcare systems, according to Moderna chief executive Stephane Bancel.
It follows a promising Phase 1/2 study in which the vaccine, mRNA-1083, demonstrated efficacy the company says is similar to or greater than existing influenza shots and comparable Covid-19 bivalent boosters.
The trial was a randomised, observer-blind study and posed no new safety concerns compared to standalone vaccines.
The superjab aims to improve public health compliance and convenience. It offers dual protection against both Covid-19 and influenza, thereby addressing the substantial global health impact of these two viruses.
Subject to regulatory approval, it is anticipated to be available in Australia by 2026.
Australian manufacturing opportunity
Australia is also set to play a pivotal role in manufacturing the vaccine – Moderna is currently constructing a facility in Melbourne, expected to be operational by 2025.
This initiative is part of a 10-year agreement with the Australian government to produce mRNA vaccines here.
Moderna plans to initiate Phase 3 trials of mRNA-1083 this year, targeting a potential 2025 approval date.
The firm expects sales from respiratory products, including the superjab, to range between US$8 billion and US$15 billion by 2027.
Meanwhile, CSL, the largest health company listed on the ASX, is also exploring a similar superjab through a licensing agreement with Arcturus Therapeutics (NASDAQ:ARCT).